UBS AM
SMMT icon

UBS AM’s Summit Therapeutics SMMT Stock Holding History

UBS AM’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
90,338
+10,642
+13% +$189K ﹤0.01% 2246
2026
Q1 		$1.51M Buy
79,696
+70
+0.1% +$1.13K ﹤0.01% 2170
2025
Q4 		$1.39M Buy
79,626
+37
+0% +$696 ﹤0.01% 2025
2025
Q3 		$1.64M Sell
79,589
-7,300
-8% -$177K ﹤0.01% 1831
2025
Q2 		$1.85M Buy
+86,889
New +$1.98M ﹤0.01% 2177
2024
Q2 		– Sell
-114,592
Closed -$474K – 2871
2024
Q1 		$474K Buy
114,592
+56,792
+98% +$226K ﹤0.01% 2303
2023
Q4 		$151K Hold
57,800
– – ﹤0.01% 2509
2023
Q3 		$108K Buy
+57,800
New +$110K ﹤0.01% 2561

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UBS AM's SMMT Position: Q2 2026 in Review

UBS AM increased its Summit Therapeutics (SMMT) stake by 13% in Q2 2026, buying an estimated $189K and bringing the position to 90,338 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2246.

UBS AM first reported a position in SMMT in Q3 2023 and has held it in 8 quarters since. The position peaked at $1.85M in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • UBS AM held 90,338 shares of Summit Therapeutics worth $1.32M as of Q2 2026.
  • UBS AM bought 10,642 Summit Therapeutics shares in Q2 2026, an estimated $189K.
  • Summit Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2246 holding.
  • UBS AM first reported a position in Summit Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • UBS AM's Summit Therapeutics position peaked at $1.85M in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.